Connecting innovation with markets in Japan and worldwide
October 7-9, 2026 | PACIFICO Yokohama | Booth C-41
Link to Document HERE
Tokyo, Japan – September 25, 2026 – Global Regulatory Partners (GRP) is pleased to announce its participation in BioJapan 2026, where GRP will exhibit at Booth C-41 and participate in the event’s international Partnering program.
BioJapan 2026 is observing its 40th anniversary as the world’s longest running biotechnology event. It is held together with concurrent events,Regenerative Medicine JAPAN, and healthTECH JAPAN, bringing together biotechnology, pharmaceuticals, regenerative medicine, digital health, academia, investors, service providers, and other life-science stakeholders from Japan and around the world.
| Helping global innovation reach Japan – and Japanese innovation reach the world |
A Market-Entry Partner Built Around the Client
Bringing an innovative healthcare product to a new market requires more than regulatory approval. Companies must gain a deep understanding of the market and determine the right regulatory pathway, operating model, local partnerships, commercialization approach, and post-market structure for their product and business objectives.
GRP helps overseas healthcare companies enter and operate in the Japanese market in the way best suited to their individual needs, taking into account the specific requirements of Japanese regulatory authorities. Our capabilities range from regulatory strategy and product registration to serving as Marketing Authorization Holder (MAH), as well as supporting quality, pharmacovigilance, medical information, market access, distribution, and other activities needed to establish and maintain products in Japan.
This flexible approach allows overseas companies to build a Japan market-entry model appropriate to their product, stage of development, resources, and long-term strategy – without necessarily having to establish and maintain all required capabilities themselves.
To make this possible, GRP has established a market-entry platform through which GRP Japan, as the MAH, supports clients from regulatory strategy through post-approval commercialization, helping maximize the return on investment of their market entry.
GRP also works in the other direction. For Japanese companies seeking opportunities outside Japan, GRP provides access to regulatory expertise and support across international markets, helping companies evaluate pathways for overseas development and commercialization and connect Japanese healthcare innovation with patients and partners globally.
Meet GRP at BioJapan 2026
Visitors are invited to meet the GRP team at Booth C-41 and through the BioJapan Partnering program to discuss:
- Japan market-entry strategies for pharmaceutical, biotechnology, medical device, diagnostic, and other healthcare products
- Marketing Authorization Holder (MAH) and in-country representation solutions
- Regulatory development and registration strategies
- Quality, pharmacovigilance, medical information, and post-market support
- Market access, commercialization, and distribution models
- International regulatory and market-entry strategies for Japanese companies expanding overseas
- Potential licensing, development, and cross-border business partnerships
Members of GRP’s senior management will be present and available for meetings throughout the event.
Whether you are an overseas innovator considering how best to enter Japan, or a Japanese company looking to take your innovation to international markets, we welcome the opportunity to discuss how GRP can help build the regulatory and commercial pathway that fits your objectives and maximize the value of your technology in your target markets.
Event Details
| Event | BioJapan 2026 |
| Dates / Venue | October 7-9, 2026 / PACIFICO Yokohama |
| GRP Booth | C-41 |
| Partnering | GRP will participate in the BioJapan Partnering program |
About Global Regulatory Partners (GRP)
Global Regulatory Partners provides regulatory, market-entry, and lifecycle support to healthcare companies seeking to bring products to markets around the world. In Japan, GRP provides end-to-end capabilities including regulatory strategy, product registration, Marketing Authorization Holder services, quality, pharmacovigilance, medical information, market access, and commercialization support. Through its international network and regulatory expertise, GRP also supports Japanese companies seeking to develop and commercialize their products globally. To learn more, visit www.globalregulatorypartners.com or, in Japan, www.globalregulatorypartners.co.jp.
